Methylenedioxypropylamphetamine

Methylenedioxypropylamphetamine (MDPA) is a psychoactive drug and research chemical of the phenethylamine and amphetamine chemical classes. It acts as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).

History[edit | edit source]

MDPA was first synthesized and patented by Alexander Shulgin in 1976. It was further researched in the 1990s due to its similarities to the popular drug MDMA (Ecstasy).

Pharmacology[edit | edit source]

MDPA inhibits the reuptake of serotonin, norepinephrine, and dopamine by binding to the transporters responsible for the reuptake of these neurotransmitters, thus increasing their extracellular concentrations and prolonging their effects.

Effects[edit | edit source]

The effects of MDPA can vary greatly depending on the dose, set, and setting. At lower doses, it can produce mild stimulant effects similar to those of amphetamine. At higher doses, it can produce effects similar to those of MDMA, including feelings of euphoria, increased sociability, and heightened sensory perception.

Legal Status[edit | edit source]

The legal status of MDPA varies by country. In the United States, it is a Schedule I controlled substance under the Controlled Substances Act. In the United Kingdom, it is a Class A drug under the Misuse of Drugs Act 1971.